Clinical trials, including Impower133 and CASPIAN, have demonstrated the first-line application of PD-L1 inhibitors could improve the survival of advanced SCLC patients (Horn et al., 2018; Paz-Ares et al., 2019). This evidence concerns the gene CD274 and small cell lung carcinoma.